PUBLISHER: The Business Research Company | PRODUCT CODE: 1674475
PUBLISHER: The Business Research Company | PRODUCT CODE: 1674475
Cell-based assays are experimental tools designed for studying reactions occurring inside cells, allowing researchers to investigate various mechanisms and processes related to cellular function.
The main products and services associated with cell-based assays include consumables, instruments, services, and software. Consumables are items that are used up or depleted during their usage. Instruments commonly used in cell-based assays encompass microplates, microplate readers, high-throughput screening systems, and liquid handling systems. Various consumables essential for these assays include reagents and media, cells and cell lines, probes, and labels. Cell-based assays employ different technologies, such as automated handling, flow cytometry, label-free detection, high-throughput screening, among others. These assays find applications in drug discovery, basic research, ADME (Absorption, Distribution, Metabolism, and Excretion) studies, predictive toxicology, and other research purposes. End-users of cell-based assays include pharmaceutical and biotechnology companies, academic and government research institutes, contract research organizations (CROs), and others.
The cell-based assays market research report is one of a series of new reports from The Business Research Company that provides cell-based assays market statistics, including cell-based assays industry global market size, regional shares, competitors with a cell-based assays market share, detailed cell-based assays market segments, market trends, and opportunities, and any further data you may need to thrive in the cell-based assays industry. This cell-based assays market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The cell based assays market size has grown strongly in recent years. It will grow from $27.07 billion in 2024 to $29.49 billion in 2025 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to emergence of HTS techniques, integration of automation, utilization of biomarker detection, adoption of microfluidics, introduction of gene editing tools.
The cell based assays market size is expected to see rapid growth in the next few years. It will grow to $48.58 billion in 2029 at a compound annual growth rate (CAGR) of 13.3%. The growth in the forecast period can be attributed to integration of ai and machine learning, shift in regulatory landscape, demand for high-content screening, advancements in disease modeling, focus on precision medicine. Major trends in the forecast period include high-throughput screening (HTA), 3d cell cultures, organ-on-a-chip technology, CRISPR/cas9 technology, advancements in imaging techniques.
The utilization of cell-based arrays in research is on the rise, necessitating a shift towards more predictive cellular models in drug discovery to mitigate last-stage failures. The pharmaceutical industry's imperative to effectively bring drugs to market and mitigate costly late-stage failures is a key driver in the innovation of cell-based assays. Failure in Phase III clinical trials of investigational new drugs (IND) can result in substantial financial losses, reaching several hundred million dollars for the company. Sigma's report indicates that the return on investment for pharmaceutical companies could plummet to 5% given the current rate of late-stage failures, an unacceptable level for most companies. Significant enhancements in high-content systems and data analysis in cell-based assays empower scientists to extract more information about cellular responses, aiding informed decision-making in drug discovery and further fueling the growth of the cell-based array market.
The rise in biologics sales is anticipated to significantly boost the cell-based assays market. Biologics, or biological products, are medicines derived from living organisms, encompassing a wide range of products such as vaccines, blood components, allergenics, somatic cells, gene therapies, tissues, and recombinant therapeutic proteins. Cell-based assays play a crucial role in the biologics sector by evaluating functionality, potency, safety, and bio-similarity. For instance, in May 2022, the European Pharmaceutical Review (EPR), a UK-based non-governmental organization, projected that biologics would greatly exceed sales of innovative small molecules in the next five years, with an estimated $120 billion increase in sales by 2027. This trend reflects a significant shift in the pharmaceutical market toward biologic products. Therefore, the growth in biologics sales is driving the expansion of the cell-based assays market.
Major companies in the cell-based assays market are increasingly launching new platforms leveraging advanced technologies, such as cell-based phenotypic assay platforms, to enhance drug discovery efforts. These platforms evaluate cellular responses to compound treatments by integrating sophisticated imaging and analytical tools, often powered by artificial intelligence. For instance, in June 2024, Sphere Fluidics, a UK-based life sciences R&D company, introduced Cyto-Cellect PLUS. This user-friendly Fluorescence Resonance Energy Transfer (FRET) assay allows researchers to accurately measure IgG productivity with high sensitivity. Building on the original Cyto-Cellect Human IgGκ Detection Kit, the enhanced version also detects both IgG κ and λ light chains, expanding its utility. The assay is fully compatible with existing Cyto-Mine(R) functionality, enabling single-cell dispensing into 96-well and 384-well plates. Additionally, it meets relevant regulatory standards by being free of animal origins, facilitating its integration into current cell line development processes. Such innovations reflect the ongoing trend toward developing advanced, user-friendly solutions in the cell-based assays market, supporting the growing demand for effective drug discovery tools.
In May 2022, Cell Carta, a Canada-based provider of precision medicine laboratory services, acquired next-generation immune-MRM assays from Precision Assays for an undisclosed amount. This acquisition aims to strengthen Cell Carta's position in the proteomics vertical and enhance its service offerings in precision medicine laboratory services. Precision Assays, a US-based provider of next-generation targeted proteomics testing solutions, played a significant role in this strategic move.
Major companies operating in the cell based assays market include F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Thermo Fisher Scientific Inc., Danaher Corporation, Becton, Dickinson and Company, GE HealthCare Technologies Inc., Corning Incorporated, Lonza Group Ltd., Charles River Laboratories International Inc., PerkinElmer Inc., Sigma-Aldrich Corporation, Bio-Rad Laboratories Inc., Miltenyi Biotec GmbH, Abcam plc, BioVision Inc., Promega Corporation, Cell Signaling Technology Inc., BioTek Instruments Inc., Enzo Life Sciences Inc., BioAgilytix Labs LLC, Cisbio International LLC, ProQinase GmbH, QGel SA, Biotium Inc., Selexis SA, Aurelia Bioscience Ltd., Creative Bioarray, Cell Biolabs Inc., Essen BioScience Ltd., Eurofins Scientific SE, DiscoveRx Corporation
North America was the largest region in the cell-based assays market in 2024. Western Europe was the second largest region in the global cell-based assays market share. The regions covered in the cell based assays market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the cell based assays market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The cell-based assay market consists of sales of reagents, cell lines, microplates, microplates, assay kits, probes, and labels. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Cell Based Assays Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on cell based assays market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for cell based assays ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cell based assays market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.